The International Agency for Research on Cancer published a report titled “Maternal Orphans due to Cancer: The intergenerational impact of cancer deaths in women,” summarizing the findings from previous publications by researchers from IARC and partners that dealt with the theme of the intergenerational impact of cancer deaths in women.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
